All manuscripts
Publications TIL Cells G-Rex®10 G-Rex®100

Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment

Published Journal Journal of Immunotherapy

Share
10 pages Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable to Numbers Needed for Patient Treatment — Journal of Immunotherapy, 2012

Overview

Details a simplified TIL production method using G-Rex®. G-Rex®10 is used for initial culture from tumor fragments/digests, and G-Rex®100 for rapid expansion (REP). This method reduces media use by 3-4 times and requires fewer vessels and labor compared to traditional 24-well plates and bags

What this paper found

Melanoma tumor infiltrating lymphocytes (TIL) can be initiated and rapidly expanded to treatment-scale numbers in gas-permeable G-Rex® flasks instead of 24-well plates, T-175 flasks and bags. In initial culture, G-Rex®10 flasks yielded TIL from 13 of 14 tumor digests with viability and CD3/CD8 phenotype similar to 24-well plates, and tumor fragments gave consistently higher yields per vessel. During rapid expansion, 5 × 10^6 TIL in a G-Rex®100 flask grew 176-fold in 7 days, versus 167-fold in T-175 flasks. A two-step 14-day process using TIL from 14 patients produced 8.60 ± 0.75 × 10^9 TIL per starting flask, a full-scale nine-flask run reached 23.6 × 10^9 cells, and interferon-γ release was similar to conventional cultures.

Note: In vitro process-development study using patient tumor samples; the authors note that G-Rex® flasks are not a closed system and that cells cannot be easily visualized.

These results suggest that TIL growth in G-Rex10 flasks is comparable with that in 24-well plates. — Jianjian Jin, Marianna Sabatino, Robert Somerville, John R. Wilson, Mark E. Dudley, David F. Stroncek, Steven A. Rosenberg, Journal of Immunotherapy

Study details

Authors
Jianjian Jin, Marianna Sabatino, Robert Somerville, John R. Wilson, Mark E. Dudley, David F. Stroncek, Steven A. Rosenberg
Institution
Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA · Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA · Wilson Wolf Manufacturing, New Brighton, MN, USA
Journal
Journal of Immunotherapy
Year
2012
PMID / PMC
PMID: 22421946 · PMC
G-Rex® model(s)
G-Rex®10, G-Rex®100
Cell type(s)
TIL Cells
Application area
Solid tumor
Study phase
Preclinical

How G-Rex® was used

Initial TIL cultures were set up in G-Rex®10 flasks (10 cm² silicone bottom, about 40 mL) from tumor digests or from 5 to 30 tumor fragments per flask, and TIL were harvested after 7 to 29 days. For rapid expansion, G-Rex®100 flasks (100 cm², about 500 mL) were seeded with 5 × 10^6 TIL, irradiated PBMC feeders at 1:100, 3000 IU/mL IL-2 and 30 ng/mL anti-CD3 in 400 mL medium, split 1:3 into three flasks on day 7 and harvested on day 14. This gave a 176-fold expansion in 7 days. In clinical-scale runs, six G-Rex®10 flasks seeded with 5 fragments each fed 18 G-Rex®100 flasks.

Explore related

Full citation

Jin J, Sabatino M, Somerville R, et al. Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment. J Immunother. 2012;35(3):283-292.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →